Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 226

1.

ALK positively regulates MYCN activity through repression of HBP1 expression.

Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, Loontiens S, Vanhauwaert S, Althoff K, Wigerup C, Bexell D, Dolman E, Henrich KO, Wehrmann L, Westerhout EM, Demoulin JB, Kumps C, Van Maerken T, Laureys G, Van Neste C, De Wilde B, De Wever O, Westermann F, Versteeg R, Molenaar JJ, Påhlman S, Schulte JH, De Preter K, Speleman F.

Oncogene. 2018 Dec 11. doi: 10.1038/s41388-018-0595-3. [Epub ahead of print]

PMID:
30538293
2.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021. [Epub ahead of print]

3.

In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors.

Vanhauwaert S, Decaesteker B, De Brouwer S, Leonelli C, Durinck K, Mestdagh P, Vandesompele J, Sermon K, Denecker G, Van Neste C, Speleman F, Preter K.

Sci Rep. 2018 Nov 30;8(1):17468. doi: 10.1038/s41598-018-35868-5.

4.

Long non-coding RNA expression profiling in cancer: challenges and opportunities.

Lorenzi L, Avila Cobos F, Decock A, Everaert C, Helsmoortel H, Lefever S, Verboom K, Volders PJ, Speleman F, Vandesompele J, Mestdagh P.

Genes Chromosomes Cancer. 2018 Nov 21. doi: 10.1002/gcc.22709. [Epub ahead of print] Review.

PMID:
30461116
5.

Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.

Emdal KB, Pedersen AK, Bekker-Jensen DB, Lundby A, Claeys S, De Preter K, Speleman F, Francavilla C, Olsen JV.

Sci Signal. 2018 Nov 20;11(557). pii: eaap9752. doi: 10.1126/scisignal.aap9752.

PMID:
30459283
6.

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.

Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, Nunes C, De Vloed F, Depuydt P, Verboom K, Rombaut D, Loontiens S, De Wyn J, Kholosy WM, Koopmans B, Essing AHW, Herrmann C, Dreidax D, Durinck K, Deforce D, van Nieuwerburgh F, Henssen A, Versteeg R, Boeva V, Schleiermacher G, van Nes J, Mestdagh P, Vanhauwaert S, Schulte JH, Westermann F, Molenaar JJ, De Preter K, Speleman F.

Nat Commun. 2018 Nov 19;9(1):4866. doi: 10.1038/s41467-018-06699-9.

7.

Meta-mining of copy number profiles of high-risk neuroblastoma tumors.

Depuydt P, Koster J, Boeva V, Hocking TD, Speleman F, Schleiermacher G, De Preter K.

Sci Data. 2018 Oct 30;5:180240. doi: 10.1038/sdata.2018.240.

8.

Pinpointing a potential role for CLEC12B in cancer predisposition through familial exome sequencing.

Derpoorter C, Vandepoele K, Diez-Fraile A, Vandemeulebroecke K, De Wilde B, Speleman F, Van Roy N, Lammens T, Laureys G.

Pediatr Blood Cancer. 2018 Oct 23:e27513. doi: 10.1002/pbc.27513. [Epub ahead of print]

PMID:
30350915
9.

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Verboom K, Van Loocke W, Volders PJ, Decaesteker B, Avila Cobos F, Bornschein S, de Bock CE, Kalender Atak Z, Clappier E, Aerts S, Cools J, Soulier J, Taghon T, Van Vlierberghe P, Vandesompele J, Speleman F, Durinck K.

Haematologica. 2018 Jun 28. pii: haematol.2018.190587. doi: 10.3324/haematol.2018.190587. [Epub ahead of print] No abstract available.

10.

LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.

Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, de Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C.

Clin Cancer Res. 2018 Nov 15;24(22):5772-5783. doi: 10.1158/1078-0432.CCR-17-2578. Epub 2018 Jun 20.

PMID:
29925504
11.

Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice.

Renard M, Vanhauwaert S, Vanhomwegen M, Rihani A, Vandamme N, Goossens S, Berx G, Van Vlierberghe P, Haigh JJ, Decaesteker B, Van Laere J, Lambertz I, Speleman F, Vandesompele J, Willaert A.

Sci Rep. 2018 May 16;8(1):7642. doi: 10.1038/s41598-018-25389-6.

12.

Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.

Garcia EG, Iyer S, Garcia SP, Loontiens S, Sadreyev RI, Speleman F, Langenau DM.

Leukemia. 2018 Aug;32(8):1860-1865. doi: 10.1038/s41375-018-0130-0. Epub 2018 Apr 18. No abstract available.

PMID:
29749398
13.

Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.

Ooi CY, Carter DR, Liu B, Mayoh C, Beckers A, Lalwani A, Nagy Z, De Brouwer S, Decaesteker B, Hung TT, Norris MD, Haber M, Liu T, De Preter K, Speleman F, Cheung BB, Marshall GM.

Cancer Res. 2018 Jun 15;78(12):3122-3134. doi: 10.1158/0008-5472.CAN-17-3034. Epub 2018 Apr 2.

PMID:
29610116
14.

Promoter-associated proteins of EPAS1 identified by enChIP-MS - A putative role of HDX as a negative regulator.

Hamidian A, Vaapil M, von Stedingk K, Fujita T, Persson CU, Eriksson P, Veerla S, De Preter K, Speleman F, Fujii H, Påhlman S, Mohlin S.

Biochem Biophys Res Commun. 2018 May 5;499(2):291-298. doi: 10.1016/j.bbrc.2018.03.150. Epub 2018 Mar 26.

PMID:
29577908
15.

A high-throughput 3' UTR reporter screening identifies microRNA interactomes of cancer genes.

Van Peer G, Mets E, Claeys S, De Punt I, Lefever S, Ongenaert M, Rondou P, Speleman F, Mestdagh P, Vandesompele J.

PLoS One. 2018 Mar 9;13(3):e0194017. doi: 10.1371/journal.pone.0194017. eCollection 2018.

16.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

17.

The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease.

De Wilde B, Beckers A, Lindner S, Kristina A, De Preter K, Depuydt P, Mestdagh P, Sante T, Lefever S, Hertwig F, Peng Z, Shi LM, Lee S, Vandermarliere E, Martens L, Menten B, Schramm A, Fischer M, Schulte J, Vandesompele J, Speleman F.

Oncotarget. 2017 Dec 22;9(9):8334-8349. doi: 10.18632/oncotarget.23614. eCollection 2018 Feb 2.

18.

Vehicle development, pharmacokinetics and toxicity of the anti-invasive agent 4-fluoro-3',4',5'-trimethoxychalcone in rodents.

Mus LM, Denecker G, Speleman F, Roman BI.

PLoS One. 2018 Feb 22;13(2):e0192548. doi: 10.1371/journal.pone.0192548. eCollection 2018.

19.

Correction to: Epigenetic regulation of neuroblastoma development.

Durinck K, Speleman F.

Cell Tissue Res. 2018 May;372(2):443. doi: 10.1007/s00441-018-2811-4.

PMID:
29396592
20.

Epigenetic regulation of neuroblastoma development.

Durinck K, Speleman F.

Cell Tissue Res. 2018 May;372(2):309-324. doi: 10.1007/s00441-017-2773-y. Epub 2018 Jan 19. Review. Erratum in: Cell Tissue Res. 2018 Feb 2;:.

PMID:
29350283

Supplemental Content

Loading ...
Support Center